The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) sells one number in bold: a 0.06% expense ratio. On $10,000 invested, that headline fee costs about $6 a year. That fee is the smallest cost this ETF quietly extracts from a taxable holder, and the March 2026 reconstitution proved it.
What You Are Actually Paying
Let’s start with what is immediately visible — the low expense ratio. At 6 basis points, SCHD looks cheap. That said, similar funds, like the Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) still charges less, at 0.04%, or about $4 per $10,000. The direct fee gap is roughly $2 a year on a $10,000 stake. Admittedly, that is a small difference. However, the real cost lies underneath.
SCHD tracks the Dow Jones U.S. Dividend 100 Index. The index reconstitutes each March, with the March 2026 reconstitution being one of the largest turnover events in fund history. Every name added or dropped forced the ETF to trade. As such, every appreciated share sold inside that trade became a realized gain the fund could pass to shareholders as a distribution.
The payout history shows this in practice. SCHD paid $0.8241 per share in Q2 2024 and $0.7545 in Q3 2024, well above the fund’s normal quarterly cadence of roughly $0.25 to $0.28. Post-reconstitution distributions like these arrive on your 1099 as income for shares you never actually sold, taxed at your income bracket in the year Schwab decides.
The Concentration the Factsheet Downplays
The May 31, 2026 NPORT filing shows how top-heavy this “diversified” ETF has become. Qualcomm (NASDAQ:QCOM | QCOM Price Prediction) alone accounts for 6.74% of net assets. Add Texas Instruments and UnitedHealth Group, and the top three positions carry 17.73% of a 102-holding portfolio.
Energy is another cluster. Chevron (NYSE:CVX) sits at 3.83%, ConocoPhillips (NYSE:COP) at 3.51%, and Devon, EOG, SLB and ONEOK fill in around them. Analyst commentary puts SCHD’s total energy weight at nearly 17%, well above the S&P 500. That said, concentration cuts both ways. Qualcomm shares are down 18.86% over the past month and 12.81% year to date, and that pain flows straight into the ETF’s largest slot.
The Performance Gap Less Talked About
Here is the part the marketing tends to skip. Since February 2022, SCHD returned 46% while dividend-growth peer CGDV returned 113%. Over the last decade, SCHD trailed WisdomTree’s DGRW by roughly 38%. The screen that excludes megacap tech and demands a 10-year dividend record seemingly has a bill attached. And that hidden cost never shows up on the expense ratio line.
Holders pay through single names too. Merck (NYSE:MRK) sits at 3.86%, Abbott Laboratories (NYSE:ABT) at 2.96%, and Altria (NYSE:MO) at 2.94%. Altria’s high yield is fully taxable at ordinary rates for most holders; SCHD’s screen accepts high-yield names like Altria because the dividend keeps coming.
The Cheaper Mirror
Investors who want broad U.S. dividend exposure with lower fees and lower turnover have options. VIG charges 0.04% and screens for consecutive dividend growers, skewing to more diversified megacaps. The trade-off is real: lower headline yield, less energy exposure, and far less reconstitution churn in your taxable account.
What This Means for You
SCHD’s 24.03% year-to-date gain is real, and the dividend growth streak is also real. However, before your next contribution, ask whether the March reconstitution tax bill, the Qualcomm-heavy top of the book, and the decade-long gap versus dividend-growth peers add up to more than the six-basis-point sticker suggests. The fee is the price on the label. The costs live underneath.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks